Jitendra Chhaganbhai Kaila

Jitendra Chhaganbhai Kaila

Active Director Managing Director DIN 06998933
DIN 06998933 First appointment Nov 2014 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 1 historical roles
Total affiliations 4 Since Nov 2014
Shareholding value •••• Premium profile

About Jitendra Chhaganbhai Kaila

Data last updated:

Jitendra Chhaganbhai Kaila is a Managing Director at Synzeal Research Private Limited (since 2014), Director at Apisyn Healthcare Private Limited (since 2020) and Director at Synzeal Pharmachem Private Limited (since 2021). The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹145 Cr; the largest is Synzeal Research Private Limited at ₹144 Cr (FY 2025). Earlier, Jitendra Chhaganbhai Kaila was a Director at Apisyn Pharmaceuticals Private Limited (from 2017).

DIN 06998933
Primary Designation Managing Director
Industry Pharma
First Appointment 20 Nov 2014
Oldest Company Age 11 yrs
Largest company Synzeal Research Private Limited · ₹144 Cr (FY 2025)
Combined revenue ₹145 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Synzeal Research Private Limited U73200GJ2014PTC081295
Managing Director20 Nov 20142014₹144 Cr (FY 2025)Active
Apisyn Healthcare Private Limited U33127GJ2020PTC113336
Director30 Mar 20202020₹98.9 Lakh (FY 2025)Active
Synzeal Pharmachem Private Limited U33119GJ2021PTC123874
Director06 Jul 20212021Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Nov 20172017Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Synzeal Pharmachem Private Limited
Apisyn Healthcare Private Limited
Apisyn Pharmaceuticals Private Limited
Synzeal Research Private Limited
Premium access

Shareholding and investment profile for Jitendra Chhaganbhai Kaila

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jitendra Chhaganbhai Kaila

Jitendra Chhaganbhai Kaila currently holds 3 directorships: Synzeal Research Private Limited (Managing Director, since 20 Nov 2014, revenue ₹144 Cr (FY 2025)); Apisyn Healthcare Private Limited (Director, since 30 Mar 2020, revenue ₹98.9 Lakh (FY 2025)); Synzeal Pharmachem Private Limited (Director, since 06 Jul 2021).

Jitendra Chhaganbhai Kaila was first appointed on 20 Nov 2014 as Managing Director at Synzeal Research Private Limited. The most recent appointment on record is 06 Jul 2021 at Synzeal Pharmachem Private Limited.

The 2 current companies of Jitendra Chhaganbhai Kaila that report revenue have a combined latest revenue of ₹145 Cr: Synzeal Research Private Limited ₹144 Cr (FY 2025); Apisyn Healthcare Private Limited ₹98.9 Lakh (FY 2025).

Jitendra Chhaganbhai Kaila held 1 earlier board appointment: Apisyn Pharmaceuticals Private Limited (Director, from 29 Nov 2017).

The current boards of Jitendra Chhaganbhai Kaila's companies include Maghabhai Haribhai Patel (Synzeal Research Private Limited), Rameshbhai Maghabhai Patel (Synzeal Research Private Limited), Shailesh M Patel (Synzeal Research Private Limited), Drashti Laxmikant Solanki (Apisyn Healthcare Private Limited), Drashti Laxmikant Solanki (Apisyn Healthcare Private Limited), Naresh Kachhadiya Maganlal (Apisyn Healthcare Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available